PC-046 is a multi-target inhibitor with antitumor activity, targeting tyrosine receptor kinase B (TrkB), IRAK-4, and Pim-1; it exhibits cytotoxicity against pancreatic cancer BxPC3 cells, induces apoptosis, and causes cell cycle arrest at the G2/M phase; it also demonstrates favorable pharmacokinetic properties in mice.